David Apelian - 03 Jul 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role
CEO, Director
Signature
/s/ David Apelian
Issuer symbol
N/A
Transactions as of
03 Jul 2023
Net transactions value
$0
Form type
4
Filing time
06 Jul 2023, 17:37:37 UTC
Previous filing
02 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +750,000 $0.000000 750,000 03 Jul 2023 Common Stock 750,000 $0.7290 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in equal monthly installments over 48 months measured from July 3, 2023, subject to the Reporting Person's continuous service as of each such date.